Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1457-1460

  Ratnavelu, Kananathan ^a   Subramani, Baskar ^b,c   Pullai, Chithra Ramanathan ^b,e   Krishnan, Kohila ^b,e   Sugadan, Sheela Devi ^b   Rao, Manjunath Sadananda ^c,d   Veerakumarasivam, Abhi ^e,f   Deng, Xuewen ^g   Hiroshi, Terunuma ^g  

^a Nilai Cancer Institute (NCI) Hospital   (Malaysia)

^b Nichi Asia Life Sdn Bhd   (Malaysia)

^c ACHARYA NAGARJUNA UNIVERSITY   (India)

^d Nichi In Centre for Regenerative Medicine (NCRM)   (India)

^e UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^f PERDANA UNIVERSITY   (Malaysia)

^g Biotherapy Institute of Japan   (Japan)

Author keywords

Advanced epithelioid sarcoma; Adverse reactions; Autologous immune enhancement therapy; Natural killer cells; T cells

Indexed keywords

CD34 ANTIGEN; CD68 ANTIGEN; CYTOKERATIN; DESMIN; DOXORUBICIN; IFOSFAMIDE; MELANIN; SMOOTH MUSCLE ACTIN; VIMENTIN;

ADJUVANT THERAPY; ADULT; ARTICLE; AUTOLOGOUS IMMUNE ENHANCEMENT THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIOID SARCOMA; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; T LYMPHOCYTE;

EID: 84875695654     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1247     Document Type: Article

References (25)

1. Demetri GD, Baker LH, Benjamin RS, et al: Soft tissue sarcoma. J Natl Compr Canc Netw 5: 364-399, 2007.
2. Pedrazzoli P, Secondino S, Perfetti V, Comoli P and MontagnaD: Immunotherapeutic Intervention against Sarcomas. J Cancer 2: 350-356, 2011.
3. Ferrari A, Miceli R, Casanova M, et al: The symptom interval in children and adolescents with soft tissue sarcomas. Cancer 116: 177-183, 2010.
4. Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin 54: 94-109, 2004.
5. Brady MS, Gaynor JJ and Brennan MF: Radiation-associated sarcoma of bone and soft tissue. Arch Surg 127: 1379-1385, 1992.
6. Zahm SH and Fraumeni JF Jr: The epidemiology of soft tissue sarcoma. Semin Oncol 24: 504-514, 1997.
7. Hardell L and Sandström A: Case-control study: soft-tissue sarcomas and exposure to phenoxyacetic acids or chlorophenols. Br J Cancer 39: 711-717, 1979.
8. Smith AH, Pearce NE, Fisher DO, Giles HJ, Teague CA and Howard JK: Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. J Natl Cancer Inst 73: 1111-1117, 1984.
9. Mori K, Rédini F, Gouin F, Cherrier B and Heymann D: Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep 15: 693-700, 2006.
10. Wolf PS, Flum DR, Tanas MR, Rubin BP and Mann GN: Epithelioid sarcoma: the University of Washington experience. Am J Surg 196: 407-412, 2008.
11. Gough NJ, Smith C, Ross JR, Riley J and Judson I: Symptom burden, survival and palliative care in advanced soft tissue sarcoma. Sarcoma 2011: 325189, 2011.
12. Coindre JM, Terrier P, Guillou L, et al: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91: 1914-1926, 2001.
13. Sinha S and Peach AH: Diagnosis and management of soft tissue sarcoma. BMJ 341: c7170, 2010.
14. Grimer R, Judson I, Peake D and Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma 2010: 506182, 2010.
15. Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 353: 701-711, 2005.
16. Buddingh EP, Schilham MW, Ruslan SE, et al: Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60: 575-586, 2011.
17. Cho D and Campana D: Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 29: 89-96, 2009.
18. Matar P, Alaniz L, Rozados V, et al: Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci 16: 30, 2009.
19. Manjunath SR, Ramanan G, Dedeepiya VD, et al: Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report. Case Rep Oncol 5: 114-118, 2012.
20. Maki RG: Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 13: 270-274, 2001.
21. Maki RG: Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 18: 363-368, 2006.
22. Takada M, Terunuma H, Deng X, et al: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18: 64-67, 2011.
23. Montagna D, Turin I, Schiavo R, et al: Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 14: 80-90, 2012.
24. Valle AA and Kraybill WG: Management of soft tissue sarcomas of the extremity in adults. J Surg Oncol 63: 271-279, 1996.
25. Francescutti V and Skitzki JJ: Sarcomas and the immune system: implications for therapeutic strategies. Surg Oncol Clin N Am 21: 341-355, 2012.